Amicus Therapeutics, Inc.
FOLD
$6.52
-$0.375-5.44%
| Weiss Ratings | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.31 | |||
| Price History | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -18.05% | |||
| 30-Day Total Return | -29.11% | |||
| 60-Day Total Return | -29.26% | |||
| 90-Day Total Return | -34.59% | |||
| Year to Date Total Return | -30.02% | |||
| 1-Year Total Return | -42.19% | |||
| 2-Year Total Return | -41.20% | |||
| 3-Year Total Return | -21.69% | |||
| 5-Year Total Return | -35.81% | |||
| 52-Week High % Change | -45.53% | |||
| 52-Week Low % Change | 11.13% | |||
| Price | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $12.65 | |||
| 52-Week Low Price | $6.20 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Nov 06, 2024 | |||
| Valuation | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.12B | |||
| Enterprise Value | 2.31B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.19 | |||
| Earnings Per Share Growth | -63.97% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.99 | |||
| Price/Book (Q) | 10.62 | |||
| Enterprise Value/Revenue (TTM) | 4.37 | |||
| Price | $6.52 | |||
| Enterprise Value/EBITDA (TTM) | 54.22 | |||
| Enterprise Value/EBIT | 67.83 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 306.14M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 609 662 2000 | |||
| Address | 47 Hulfish Street Princeton, NJ 08542 | |||
| Website | amicusrx.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 6.44% | |||
| Profit Margin | -10.62% | |||
| Management Effectiveness | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 2.72% | |||
| Return on Equity | -- | |||
| Income Statement | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 528.30M | |||
| Total Revenue (TTM) | 528.30M | |||
| Revenue Per Share | $1.73 | |||
| Gross Profit (TTM) | 475.35M | |||
| EBITDA (TTM) | 42.61M | |||
| EBIT (TTM) | 34.06M | |||
| Net Income (TTM) | -56.11M | |||
| Net Income Avl. to Common (TTM) | -56.11M | |||
| Total Revenue Growth (Q YOY) | 30.09% | |||
| Earnings Growth (Q YOY) | 143.55% | |||
| EPS Diluted (TTM) | -0.19 | |||
| EPS Diluted Growth (Q YOY) | 142.76% | |||
| Balance Sheet | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 249.95M | |||
| Cash Per Share (Q) | $0.82 | |||
| Total Current Assets (Q) | 504.74M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 194.05M | |||
| Current Ratio (Q) | 3.394 | |||
| Book Value Per Share (Q) | $0.65 | |||
| Total Assets (Q) | 785.03M | |||
| Total Current Liabilities (Q) | 148.70M | |||
| Total Debt (Q) | 443.64M | |||
| Total Liabilities (Q) | 590.99M | |||
| Total Common Equity (Q) | 194.05M | |||
| Cash Flow | FOLD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -560.00K | |||
| Cash from Financing (TTM) | 5.12M | |||
| Net Change in Cash (TTM) | -33.36M | |||
| Levered Free Cash Flow (TTM) | 5.41M | |||
| Cash from Operations (TTM) | -33.89M | |||
